Cargando…

A retrospective analysis of cytogenetic alterations in patients with newly diagnosed multiple myeloma: a single center study in Korea

BACKGROUND: The accurate identification of cytogenetic abnormalities in multiple myeloma (MM) has become more important over recent years for the development of new diagnostic and prognostic markers. In this study, we retrospectively analyzed the cytogenetic aberrations in MM cases as an initial ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shuhua, Lim, Hyeon-Ho, Woo, Kwang-Sook, Kim, Sung-Hyun, Han, Jin-Yeong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931930/ https://www.ncbi.nlm.nih.gov/pubmed/27382557 http://dx.doi.org/10.5045/br.2016.51.2.122

Ejemplares similares

Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma
por: Lee, Nuri, et al.
Publicado: (2021)

PB2023: UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC).
por: Nuevo López, M. I., et al.
Publicado: (2022)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
por: Binder, M, et al.
Publicado: (2017)

P-208: Association of thrombocytopenia with disease burden, high-risk cytogenetics, and survival in newly diagnosed multiple myeloma patients
por: Charalampous, Charalampos, et al.
Publicado: (2022)

P26 LANDSCAPE OF RECURRENT CYTOGENETIC ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AS DETECTED BY CHROMOSOME MICROARRAY ANALYSIS (CMA)
por: Varshavsky Yanovsky, A., et al.
Publicado: (2023)

Diagnostic Utility of Multiprobe Fluorescence in situ Hybridization Assay for Detecting Cytogenetic Aberrations in Acute Leukemia
por: Kim, Bo-Ram, et al.
Publicado: (2014)

STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma
por: Park, Sung-Soo, et al.
Publicado: (2023)

Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma
por: Batsukh, Khishigjargal, et al.
Publicado: (2017)

The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma
por: Yang, Peiyu, et al.
Publicado: (2022)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations
por: Zhao, Duoduo, et al.
Publicado: (2023)

Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China
por: Zhuang, Zhe, et al.
Publicado: (2023)

Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India
por: Govindasamy, Perumal, et al.
Publicado: (2019)

Profiles and Clinical Characteristics of Newly Diagnosed Glaucoma in Urban Korea: A Multicenter Study
por: Hong, Chul, et al.
Publicado: (2020)

Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer
por: Gunn, Shelly, et al.
Publicado: (2013)

Clinical characteristics and nursing diagnoses of pediatric patients hospitalized with inflammatory bowel disease: a single-center retrospective study in South Korea
por: Jo, Sung-Yoon, et al.
Publicado: (2023)

Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
por: Kim, Dae Sik, et al.
Publicado: (2017)

PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA
por: Zhuang, Z., et al.
Publicado: (2022)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression
por: Li, Can, et al.
Publicado: (2021)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
por: Hsu, Pei, et al.
Publicado: (2015)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022)

Anorectal Manometric Dysfunctions in Newly Diagnosed, Early-Stage Parkinson's Disease
por: Sung, Hye Young, et al.
Publicado: (2012)

Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study
por: Chen, Runzhe, et al.
Publicado: (2017)

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study
por: Greenberg, A J, et al.
Publicado: (2015)

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study
por: Greenberg, A J, et al.
Publicado: (2015)

Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT 3‐ITD AML
por: Buelow, Daelynn R., et al.
Publicado: (2019)

PB2027: EFFICACY OF THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROME WITH UNFAVORABLE IMMUNOPHENOTYPIC AND CYTOGENETIC PROGNOSIS.
por: Trubkina, Hanna, et al.
Publicado: (2023)

A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma
por: Chang, Hye Jung, et al.
Publicado: (2011)

PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
por: Moutmir, Yasmine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3gqmtk9gtg9qalvvgb96fvi44l